0001583682-19-000002.txt : 20190829 0001583682-19-000002.hdr.sgml : 20190829 20190829171336 ACCESSION NUMBER: 0001583682-19-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190829 DATE AS OF CHANGE: 20190829 EFFECTIVENESS DATE: 20190829 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Antibe Therapeutics Inc. CENTRAL INDEX KEY: 0001583682 IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-347707 FILM NUMBER: 191067182 BUSINESS ADDRESS: STREET 1: 15 PRINCE ARTHUR AVENUE CITY: TORONTO STATE: A6 ZIP: M5R 1B2 BUSINESS PHONE: 905.726.0995 MAIL ADDRESS: STREET 1: 15 PRINCE ARTHUR AVENUE CITY: TORONTO STATE: A6 ZIP: M5R 1B2 D 1 primary_doc.xml X0708 D LIVE 0001583682 Antibe Therapeutics Inc. 15 PRINCE ARTHUR AVENUE TORONTO A6 ONTARIO, CANADA M5R 1B2 905-570-5103 ONTARIO, CANADA None None Corporation true DANIEL LEGAULT 15 PRINCE ARTHUR AVENUE TORONTO A6 ONTARIO, CANADA M5R 1B2 Executive Officer Director ALAIN WILSON 15 PRINCE ARTHUR AVENUE TORONTO A6 ONTARIO, CANADA M5R 1B2 Executive Officer WALT MACNEE 15 PRINCE ARTHUR AVENUE TORONTO A6 ONTARIO, CANADA M5R 1B2 Director AMAL KHOURI 15 PRINCE ARTHUR AVENUE TORONTO A6 ONTARIO, CANADA M5R 1B2 Director JOHN WALLACE 15 PRINCE ARTHUR AVENUE TORONTO A6 ONTARIO, CANADA M5R 1B2 Director YUNG WU 15 PRINCE ARTHUR AVENUE TORONTO A6 ONTARIO, CANADA M5R 1B2 Director RODERICK FLOWER 15 PRINCE ARTHUR AVENUE TORONTO A6 ONTARIO, CANADA M5R 1B2 Director Biotechnology $5,000,001 - $25,000,000 06b false 2019-08-13 true true true true true Each Unit consists of one common share and one-half of one common share purchase warrant. Each warrant is exercisable for one-half of one common share at an exercise price of $0.40 per common share for a period of 36 months. false 0 HAYWOOD SECURITIES (USA) INC. 42072 HAYWOOD SECURITIES INC. None 200 BURRARD STREET SUITE 700 VANCOUVER A1 BRITISH COLUMBIA, CANADA V6C 3L6 PA PENNSYLVANIA false 4337918 283319 4054599 The additional $4,054,599.00 may be received upon the exercise of share purchase warrants sold inside or outside the U.S. The U.S. dollar amounts are based on the Bank of Canada average rate of exchange reported on 08/13/19, which was Cdn$1.3236=USD$1.00. false 1 19832 true 0 0 In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors. false Antibe Therapeutics Inc. SCOTT CURTIS SCOTT CURTIS VP, CORPORATE DEVELOPMENT 2019-08-20